Treatment Characteristics
| Characteristic | Data |
| Total SIRT (n) | 29 (100%) |
| SIRT per patient (n) | |
| 1 | 16 (73%) |
| 2 | 5 (23%) |
| 3 | 1 (5%) |
| Liver treatment (n) | |
| Whole liver in single session | 9 (41%) |
| Whole liver in multiple sessions | 5 (23%) |
| Lobar only | 8 (36%) |
| Sum of administered activities per patient (GBq) | |
| Mean | 2.1 (95%CI, 1.7–2.5) |
| Median | 1.8 (range, 1–2.8) |
| Mean administered activity per patient (GBq) | |
| Mean | 1.7 (95%CI, 1.5–1.9) |
| Median | 1.6 (range, 0.7–2.8) |
| Highest administered activity per patient (GBq) | |
| Mean | 1.8 (95%CI, 1.5–2.1) |
| Median | 1.6 (range, 1–3) |
| Dose to tumor (Gy) | |
| Mean | 171.7 (95%CI, 142.5–200.9) |
| Median | 155.4 (range, 43.9–356) |
| Dose to healthy liver (Gy) | |
| Mean | 50.4 (95%CI, 42.6–58.2) |
| Median | 46.2 (range, 21–99.1) |
| Dose to lungs (Gy) | |
| Mean | 1.3 (95%CI, 1.0–1.6) |
| Median | 1.1 (range, 0.1–2.9) |
| Type of 90Y-microspheres (n) | |
| TheraSphere | 5 (23%) |
| SIR-Spheres | 19 (86%) |
| Both | 2 (9%) |
| Post-SIRT systemic therapies (n) | |
| Chemotherapy | 11 (50%) |
| Immunotherapy | 13 (59%) |
| Both | 7 (32%) |
| Post-SIRT locoregional therapies (n) | |
| Transarterial chemoembolization | 4 (18%) |
| Thermal ablation | 5 (23%) |
| Both | 0 (0%) |